Global Health Limited (MEDANTA)
🎯 Key Takeaways
- Global Health Limited is in a growth phase, transitioning from operational scaling to profitability consolidation, marked by consistent revenue expansion, margin improvement, and strategic leadership appointments. The company has demonstrated steady financial performance with rising profitability and EPS growth over recent quarters, supported by expansion into new healthcare verticals and infrastructure.
- Revenue declined 1.4% QoQ to ₹943 in Q3FY25.
- ⚠️ High valuation (P/E of 65.8) may limit upside if growth slows.
📖 The Story
Global Health Limited is in a growth phase, transitioning from operational scaling to profitability consolidation, marked by consistent revenue expansion, margin improvement, and strategic leadership appointments. The company has demonstrated steady financial performance with rising profitability and EPS growth over recent quarters, supported by expansion into new healthcare verticals and infrastructure. Management is focused on sustaining momentum through targeted investments and talent acquisition, while maintaining shareholder returns via dividends.
📰 What's Happening
In the latest developments, the board approved FY2026 audited results showing ₹1,275.58 million total comprehensive income and ₹18.46 EPS, recommending a final dividend of ₹0.50 per share. The company appointed Kedar Ashok Apte as Chief Marketing & Growth Officer and Jagdeep Singh as General Counsel effective May 14, 2026, while accepting the resignation of SMP Richa Singh. Additionally, 15,900 equity shares were allotted under the ESOP 2024 to employees at a premium, increasing paid-up capital and total outstanding shares. These moves underscore a strategic emphasis on growth leadership and employee retention.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Q4FY23 | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 703 | 773 | 844 | 833 | 809 | 861 | 957 | 943 |
| Operating Profit | 192 | 199 | 234 | 234 | 207 | 208 | 247 | 254 |
| OPM % | 23.2% | 23.0% | 25.2% | 25.5% | 22.2% | 21.6% | 23.9% | 25.2% |
| Net Profit | 101 | 102 | 125 | 124 | 127 | 106 | 131 | 143 |
| EPS | ₹3.77 | ₹3.80 | ₹4.66 | ₹4.61 | ₹4.74 | ₹3.96 | ₹4.87 | ₹5.32 |
The company has delivered sequential revenue growth from ₹703 crore in Q4FY23 to ₹943 crore in Q3FY25, with operating margins expanding from 23.2% to 25.2% and net profit rising from ₹101 crore to ₹143 crore over the same period. EPS has grown from ₹3.77 to ₹5.32, reflecting improved operational efficiency and scale. This upward trajectory aligns with management's focus on margin enhancement and expansion into higher-value services, as highlighted in the board meeting commentary on exceptional items and lease approvals for new hospitals.
🔮 Management Outlook & What's Next
Management did not provide explicit forward guidance in the latest filings, including the FY2026 results announcement and earnings call scheduled for May 15, 2026. While the board emphasized confidence in financial health and approved strategic appointments and capital allocations, no projections or growth targets were disclosed. The absence of forward-looking statements suggests caution, but the approved dividend and infrastructure investments imply continued investment in scalable healthcare delivery models.
Extracted from official company announcements. Not StockFin.ai's opinion.
⚖️ Peer Comparison — Healthcare Services
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | 1.16 L Cr | 64.5 | 20.5% | 21.9% | 0.64 |
| Max Healthcare Institute Limited | 1.02 L Cr | 101.2 | — | — | — |
| Fortis Healthcare Limited | 72,752 | 94.6 | — | — | — |
| Aster DM Healthcare Limited | 39,048 | 7.1 | — | — | — |
| Narayana Hrudayalaya Ltd. | 37,625 | 47.7 | — | — | — |
| Global Health Limited | 33,405 | 65.8 | — | — | — |
| Krishna Institute of Medical Sciences Limited | 30,477 | 80.3 | — | — | — |
| Dr. Lal Path Labs Ltd. | 26,871 | 63.6 | — | — | — |
| Syngene International Limited | 18,295 | 36.3 | — | — | — |
| Dr. Agarwal's Health Care Limited | 14,266 | 88.8 | 14.9% | 6.8% | 0.13 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. High valuation (P/E of 65.8) may limit upside if growth slows. 2. Dependence on expansion into new healthcare verticals introduces execution risk. 3. Margin gains are partly driven by exceptional items like stamp duty reversals, which may not be sustainable. 4. Leadership transitions, while strategic, could introduce short-term operational disruptions if not integrated smoothly.
📋 Recent Filings
-
Announcement 13 June 2026Global Health Limited announced its upcoming investor relations schedule, confirming meetings with JP Morgan on June 17 and IIFL Capital on June 18, b...
-
Announcement 12 June 2026Global Health Limited announced it received a Letter of Intent from Haryana's Medical Education Department to establish a 150-seat medical college at ...
-
Announcement 10 June 2026Global Health Limited announced an investor meeting scheduled for June 15, 2026, in Gurugram, conducted in person, to discuss its operations with anal...
-
Announcement 8 June 2026Global Health Limited announced a one-on-one investor meeting with analysts on June 11, 2026, in Gurugram, organized by Emkay Investment Managers, to ...
-
Announcement 1 June 2026Global Health Limited announced a virtual one-on-one investor meeting with Prudent Corporate Advisory Ltd on June 4, 2026, as part of scheduled analys...
-
🔴 Corporate Action 23 May 2026Global Health Limited announced the allotment of 15,900 equity shares of Rs. 2 face value at a premium of Rs. 1,239 per share to the GHL Employees Wel...
-
🔴 Financial Results 15 May 2026Global Health Limited announced an earnings conference call on May 15, 2026 at 2:00 PM IST to discuss fourth quarter and FY2026 financial results, hos...
-
🔴 Financial Results 14 May 2026Global Health Limited reported FY2026 total income of **₹38,157.86 crores** and profit after tax of **₹4,962.01 crores**, approved a final dividend of...
-
🔴 Corporate Action 14 May 2026No summary available
-
🟡 Board Meeting 14 May 2026Global Health Limited's board approved audited FY2026 results showing ₹1,275.58 million total comprehensive income and ₹18.46 EPS, recommended a final...
🧠 Analyst's Read
Global Health Limited is executing a clear growth strategy supported by improving financial trends and strategic leadership hires, but lacks forward guidance, leaving investors to interpret momentum from past performance. The next catalyst will be the May 15 earnings call, where clarity on growth drivers and margin trajectory will be critical for assessing sustainability.
Based on filing content and financial data. Not a recommendation.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-06-16.